Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation
Information source: Capital Medical University
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Invasive Pulmonary Aspergillosis
Intervention: Amphotericin B (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Capital Medical University
Summary
The purpose of this study is to determine whether inhalation with aerosolized amphoterin B
10mg/d is more effective than aerosolized amphoterin B 2mg/d to reduce the incidence of
invasive pulmonary aspergillosis.
Clinical Details
Study design: Prevention, Randomized, Single Blind (Subject), Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: invasive pulmonary aspergillosis
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 65ys≥age≥18ys
- renal transplant recipients
Exclusion Criteria:
- subjects with hypersensitivity to amphotericin B
- receipt of inhalational or intravenous amphotericin B within last 30 days
- subjects with known invasive fungal infection before renal transplant
- subjects with pneumonia
Locations and Contacts
Beijing Chaoyang Hospital,Affiliate of Capital Medical University, Beijing 100020, China; Recruiting
Bin Cao, doctor, Phone: 8610-85231130, Email: caobin1999@gmail.com
Additional Information
Starting date: June 2008
Ending date: October 2010
Last updated: September 29, 2009
|
